A pilot study on efficacy and safety of 100 ug start dose wasp venom immunotherapy (VIT)

A pilot study on efficacy and safety of 100 ug start dose wasp venom immunotherapy (VIT) - EVVIT100

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON38607

Enrollment

Registered

2013-04-23

Start date

2013-05-14

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insect venom hypersensitivity wasp venom allergy

Interventions

zie protocol

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - A positive history of a systemic response grade II/III/IVa after vespid sting - Specific serum IgE > 0.7 kU/ - Positive intracutaneous skin test for vespid venom ( at

Exclusion criteria

Exclusion criteria: - A positive history of a systemic response grade IVb according to Müller after a vespid sting - Age under 18 years or above 65 years - Severe cardiopulmonary disease (clinical evidence of congestive heart failure, coronary disease or severe hypertension) - Insufficiently controlled asthma, especially if FEV1 is 70% of predicted. - Conditions that influence the immune system (immune deficiencies, malignancy, auto-immune diseases) - Severe kidney failure - Interfering medication with the outcome or recovery from a systemic reaction (β-blockers and immunosuppressive drugs) - Allergy to auxiliary matter in Pharmalgen® Vespula spp. - Pregnancy - Mastocytosis

Design outcomes

Primary

Measure	Time frame
zie protocol	—

Secondary

Measure	Time frame
zie protocol	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)